ÃÖÀ±½Ä(Choi Yun-Sik) - Ewha Womans University Department of Life Sciences
ÀÌ»óÇõ(Lee Sang-Hyuk) - Ewha Womans University Department of Life Sciences
(Kim Kap-Youl) - Ewha Womans University Department of Life Sciences
±è¼öÇö(Kim Soo-Hyun) - Catholic University College of Medicine Department of Microbiology
Á¤¿¬ÁØ(Chung Yeun-Jun) - Catholic University College of Medicine Department of Microbiology
(Lee Charles) - Ewha Womans University Department of Life Sciences
Abstract
Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient¡¯s own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.
Å°¿öµå
Cancer immunotherapy, Cancer models
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This review discussed advantages and disadvantages of cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.